1 Patients with advanced or metastatic cancer that is refractory to standard therapy relapsed after standard therapy or have no standard therapy that induces a complete response of at least 10 or improves survival by at least three months In addition patients with diseases that are benign by pathology but relentlessly progressive leading to disability pain and premature death in the majority of cases including but not limited to lymphangioleiomyomatosis LAM type 2 neurofibromatosis NF Erdheim Chester disease and Castleman 's disease may also be considered for enrollment 